JV will Establish Company’s 4th International Center
“We believe that this joint venture with HSJ is a testament to AMS’ global expansion plans and is ripe with opportunity. This is an exciting transaction for AMS, and the second expansion of our international strategy into Mexico, where we will soon begin treating patients with our state of the art Elekta Linear Accelerator Versa HD at our AB Radiocirugia y Radioterapia facility in Puebla. These two operations are in addition to our existing international Gamma Knife centers in Peru and Ecuador,”
Ray Stachowiak, Executive Chairman and CEO of American Shared Hospital Services.
“As one of only two Gamma Knife facilities in the entire country of Mexico with a population of 130 million people, the Joint Venture will be at the forefront of noninvasive brain treatments in this major Latin American territory. We are excited to partner with HSJ to introduce this advanced treatment modality and provide much needed access to Mexico’s patient population.”
Ernest R. Bates, VP of Sales and Business Development at AMS
“Our medical staff has been providing Gamma Knife ® radiosurgery treatments with great success since we opened our doors for business in 1994. Upgrading our current system with the Esprit, the latest model and first of its kind in Mexico, gives us multiple clinical options. Now we can offer even more personalized and patient-friendly treatments. Patients can return home the same day and resume their normal activities shortly after. We are excited to enter into our partnership with AMS and appreciate its support in bringing Esprit to our hospital.”
AMS’ JV partner, Ms. Elvia Zazueta
This press release may be deemed to contain certain forward-looking statements with respect to the financial condition, results of operations and future plans of American Shared Hospital Services including statements regarding the expected continued growth of the Company and the expansion of the Company’s Gamma Knife, proton therapy and MR/LINAC business, which involve risks and uncertainties including, but not limited to, the risks of economic and market conditions, the risks of variability of financial results between quarters, the risks of the Gamma Knife and proton therapy businesses, the risks of changes to CMS reimbursement rates or reimbursement methodology, the risks of the timing, financing, and operations of the Company’s Gamma Knife, proton therapy, and MR/LINAC businesses, the risk of expanding within or into new markets, the risk that the integration or continued operation of acquired businesses could adversely affect financial results and the risk that current and future acquisitions may negatively affect the Company’s financial position. Further information on potential factors that could affect the financial condition, results of operations and future plans of American Shared Hospital Services is included in the filings of the Company with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for the year ended December 31, 2023, and the definitive Proxy Statement for the Annual Meeting of Shareholders that was held on June 25, 2024.
